The
AMP-activated protein kinase-related kinase (ARK) family comprises 13 proteins,
amongst them NUAK1, that can be classified into five subfamilies: AMP-activated
protein kinase (AMPK), salt-induced kinase (SIK),
microtubule-affinity-regulating kinase (MARK), brain specific kinase (BRSK),
and SNF1-like kinase 1 (NUAK). These proteins regulate biological responses
such as metabolism, polarity, cell proliferation or cell death, presumably in a
sub-family specific manner [11]. Although the
different proteins regulate different responses, their activities are thought
to be controlled by the same kinase, LKB1 [2], which
phosphorylates a threonine residue in the conserved T-loop of ARK proteins.
AMPK proteins are phosphorylated and activated by LKB1 when ATP levels
decrease, whereas ARK proteins are phosphorylated and activated independently
of intracellular ATP levels [1].During
metabolic stress, ATP levels decrease and LKB1 activates AMPK that, in turn,
phosphorylates a subset of proteins. P53 has been identified as one of these
proteins, and it is postulated that the phosphorylation and activation of p53
by AMPK leads to cell cycle arrest and senescence [3].We have recently identified and described
the role of NUAK1 in the regulation of replicative senescence. Indeed, the
constitutive expression of NUAK1 induces senescence in WI38 normal human
fibroblasts whereas its knockdown extends their replicative lifespan. The loss of NUAK1
activation by LKB1 (by using a NUAK1NUAK1
mutant unresponsive to LKB1 or by inhibiting LKB1 activity in NUAK1 expressing
cells) results in a failure of NUAK1 to induce senescence, thus demonstrating
the major role of LKB1 in NUAK1-induced senescence. Interestingly, our results
support the existence of a p53 independent response, at least in WI38 cells,
and emphasize a potential role of aneuploidy in NUAK1-dependent senescence [4].
Aneuploidy
and senescence
Aneuploidy
or genomic instability due to various factors have been reported to induce
senescence [5, 6, 7].
Interestingly, senescent cells often display elevated aneuploidy, which
suggests a putative functional role of aneuploidy in senescence. Nevertheless,
it is unclear whether aneuploidy is involved in the establishment of the
senescent phenotype and, if prevented, it can impair senescence, at least to
some extent. A breakthrough has been achieved with the demonstration that the
state of irreversible growth arrest in senescent cells may be due to elevated
aneuploidy, putatively through a decrease of LATS1, a kinase involved in
mitotic exit [7]. These
results suggest that aneuploidy, if not directly involved in the establishment
of senescence, can be required for irreversible growth arrest in senescent
cells.Interestingly,
aneuploidy was also observed during replicative senescence and during
NUAK1-induced premature senescence in our model. More importantly, the
replicative lifespan extension due to NUAK1 knockdown correlated with normal
ploidy. Altogether, these results suggest that ploidy can be a functional
regulator of the senescence program.We also identified LATS1 as a potential target of
NUAK1 and a putative regulator of ploidy in NUAK1-dependent senescence.
Altogether, these results suggest that aneuploidy could be part of the
endogenous senescence program. Its mis-regulation could therefore induce
premature senescence through a process that we chose to term
"aneuploidy-induced senescence" (AIS). Our results also suggest that
AIS may occur, at least in some settings, without the involvement of the p53
pathway. Interestingly, others have described that the overexpression of Aurora
A, a serine threonine kinase tightly associated with the mitotic process,
induces senescence in the mammary gland of p53-deficient mice [8]. Hence
aneuploidy could be one of the signals triggering senescence and could act, in
some settings, independently of p53.
Aneuploidy-induced senescence as a possible safeguard
against tumor formation and development
Oncogene activation is one of the hallmarks of cancer
cells and a driving force in tumorigenesis [9].
Oncogene-induced senescence (OIS) was described about a decade ago [10], and a long
debate has raged about its relevance. With the development of adequate mouse
models of cancer susceptibility and new tools to detect senescence in vivo,
it has become possible do demonstrate its effectiveness in blocking malignant
transformation [11].Aneuploidy, another classical hallmark of cancer
cells, is also believed to be involved in tumorigenesis [12]. As
mentioned above, induction of aneuploidy can result in premature senescence in
various settings [5, 6, 7].
Together, these observations suggest that AIS, like OIS, could constitute a
failsafe mechanism against early tumorigenesis. To validate this hypothesis, it
would be interesting to test the presence and the frequency of aneuploidy in
benign lesions and to identify the genetic events possibly favoring AIS escape.The AIS model could resolve the apparent
discrepancy about the role of NUAK1 in tumorigenesis. Our recent findings
demonstrate an ability of NUAK1 to induce premature senescence in normal human
cells whereas others, mainly the team of H. Esumi, have demonstrated a pro
tumoral effect of NUAK1 through promoting cell growth and invasion [13, 14, 15]. However,
these last conclusions were based on data obtained in cancer cell lines, in
particular in colon cancer cell lines known to be highly aneuploid [16]. Thus, NUAK1
may have no additional effect on genomic stability and instead regulate other
targets to confer a growth advantage to the cells. NUAK1 might even add more
genomic instability, thus conferring additional growth and invasion advantages
to these cancer cells.
Authors: Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson Journal: Mol Cell Date: 2005-04-29 Impact factor: 17.970
Authors: Nicolas Humbert; Naveenan Navaratnam; Arnaud Augert; Marco Da Costa; Sébastien Martien; Jing Wang; Dolores Martinez; Corinne Abbadie; David Carling; Yvan de Launoit; Jesus Gil; David Bernard Journal: EMBO J Date: 2009-11-19 Impact factor: 11.598
Authors: Darren J Baker; Karthik B Jeganathan; J Douglas Cameron; Michael Thompson; Subhash Juneja; Alena Kopecka; Rajiv Kumar; Robert B Jenkins; Piet C de Groen; Patrick Roche; Jan M van Deursen Journal: Nat Genet Date: 2004-06-20 Impact factor: 38.330